BridgeBio Pharma Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Okay, everyone. We'll continue with the next session. I'm Paul Choi, the SMid-cap biotechnology analyst here at Goldman Sachs. And it's my pleasure to have BridgeBio Pharma present here. Joining us from BridgeBio is Neil Kumar, CEO.
What we'll do as in prior sessions, is I'll turn it over to Neil, maybe for some opening remarks or comments on the shape of what BridgeBio is doing here in 2021 and 2022, and then we'll go into Q&A. If investors along the way have any questions, as in prior sessions, please feel free to submit them through the webcast portal. Alternatively, you can e-mail them to me and, time permitting, I'll ask them of Neil. And with that, I'll turn it over to Neil.
Great. Well, thanks, Paul, so much for the opportunity to participate in the conference. I really appreciate the time and the chat today. I'll make my opening comments brief because it'd be great to get into the Q&A.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
